Novel oral anticoagulants in acute coronary syndrome

C. Costopoulos, M. Niespialowska-Steuden, N. Kukreja, Diana Gorog

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)


Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide with a prevalence that has now reached pandemic levels as a consequence of the rapid modernization of the developing world. Its presentation as an acute coronary syndrome (ACS) is a frequent reason for hospital admission and of profound implications for personal, societal and global health. Despite improvements in the management of ACS with anti-platelet and anticoagulant therapy and revascularization techniques, many patients continue to suffer recurrent ischemic events. The need to reduce future cardiovascular events has led to the development of novel therapies to prevent coronary thrombosis, targeting thrombin-mediated pathways. These include direct Xa inhibitors (apixaban, rivaroxaban and darexaban), direct thrombin inhibitors (dabigatran) and PAR 1 antagonists (vorapaxar and atopaxar). This article critically reviews the comparative mechanisms of action, the risks and benefits, together with the clinical evidence base for the use of these novel oral agents in the management of ACS patients.
Original languageEnglish
Pages (from-to)2449-2455
JournalInternational Journal of Cardiology
Issue number6
Publication statusPublished - 10 Sept 2013


Dive into the research topics of 'Novel oral anticoagulants in acute coronary syndrome'. Together they form a unique fingerprint.

Cite this